BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Continue Entecavir Rollover From China
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 600
- Registration Number
- NCT00975091
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1
- Registration Number
- NCT00971841
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6
- Registration Number
- NCT00971945
- Locations
- 🇯🇵
Local Institution, Toshima-ku, Tokyo, Japan
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT00971867
- Locations
- 🇯🇵
Local Institution, Tochigi, Japan
Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus
- First Posted Date
- 2009-09-03
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 37
- Registration Number
- NCT00971308
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Elite Research Institute, Miami, Florida, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
Single Dose Study of BMS-820836
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 68
- Registration Number
- NCT00964912
- Locations
- 🇨🇦
Local Institution, Toronto, Ontario, Canada
Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 64
- Registration Number
- NCT00949767
- Locations
- 🇸🇪
Local Institution, Uppsala, Sweden
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 28
- Registration Number
- NCT00948389
- Locations
- 🇨🇭
Local Institution, Lausanne, Switzerland
Japanese Bridging Study Conducted in the United States
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00947245
- Locations
- 🇺🇸
Local Institution, Cypress, California, United States
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
Phase 1
Completed
- Conditions
- Renal Cell CarcinomaNon-hodgkin's Lymphoma
- Interventions
- Biological: MDX-1203
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2013-05-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT00944905
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸The University of Michigan Health System, Ann Arbor, Michigan, United States
© Copyright 2025. All Rights Reserved by MedPath